Kratom is sold as powder, capsules, shots, drinks and gummies. Its active alkaloids affect opioid receptors, and repeated use can lead to dependence and withdrawal.
Kratom comes from Mitragyna speciosa leaves. Mitragynine and related alkaloids act on opioid receptors. People report dependence, withdrawal, seizures, liver injury and serious poisonings. Not every product has the same composition or risk, and a natural label is not proof of safety.
Straight answers about kratom leaf, extracts, dependence, adverse effects and what families should do in an emergency.
Kratom is the leaf of the Southeast Asian tree Mitragyna speciosa. Its principal alkaloid, mitragynine, interacts with mu-opioid receptors and other biological targets. Products range from dried leaf and capsules to concentrated extracts and beverages.
Yes. The opioid-receptor activity is not limited to synthetic products. Whole leaf contains mitragynine and other alkaloids. Its chemical profile and typical exposure differ from concentrated 7-hydroxymitragynine (7-OH) and other enhanced products; the risks should not be treated as identical.
Kratom leaf naturally contains mitragynine and smaller amounts of other alkaloids. 7-hydroxymitragynine is an opioid-active derivative found at low or variable levels in leaf and can also be manufactured or concentrated. Mitragynine pseudoindoxyl is another potent opioid-active compound. A product labeled “kratom” does not tell you which compounds or amounts are present. See the separate substance guides for details.
Yes. Regular users may develop tolerance, cravings and withdrawal when they reduce or stop. Reported symptoms include anxiety, restlessness, insomnia, gastrointestinal upset, sweating and muscle aches. Severity varies. A clinician can assess dependence and treatment options; do not assume every person needs the same treatment.
Poison centers, case reports and clinical studies describe nausea, vomiting, agitation, sedation, seizures, liver injury and cardiovascular effects. Fatal cases with mitragynine detected have also been reported, often involving other substances. Detection does not by itself establish that kratom caused a death.
Often. Extracts can contain higher concentrations of mitragynine per serving, and some enhanced products contain additional opioid-active alkaloids. Dose, labeling accuracy and co-ingredients vary. Do not assume two similarly sized bottles have comparable strength.
Depending on local law, kratom products may appear in smoke shops, vape shops, convenience stores and online. Marketing may emphasize energy, mood, focus, relaxation or plant origins. These claims do not establish safety or FDA approval.
The FDA has not approved kratom to treat any medical condition. Federal controlled-substance status, state restrictions and rules for particular compounds are different legal questions and can change. A product being offered for sale does not mean it has been reviewed or approved by the FDA.
If someone is unresponsive, breathing slowly or not breathing normally, call 911 immediately. Give naloxone if available and follow dispatcher instructions, including rescue breathing or CPR as directed. Naloxone may help with opioid effects, but its response in kratom-related toxicity can be variable. For non-emergency poison advice in the U.S., call Poison Control at 1-800-222-1222.
Speak with a healthcare professional experienced in substance use disorders. Treatment may include counseling, management of withdrawal symptoms and, for some patients with opioid use disorder, medication treatment based on individual assessment. Visit the Get Help page for support resources.
These products do not look like dangerous drugs. They look like snacks, drinks, wellness products, gaming products, or trendy supplements. That is exactly why communities should be alarmed.
The most disturbing part is not just that kratom exists. It is that these products are dressed up to look ordinary, friendly, and safe while being sold in everyday places where families, workers, students, and people in recovery shop.
Mitragynine interacts with opioid receptors; leaf products are not pharmacologically inert.
Tolerance, physical dependence and withdrawal are documented with repeated kratom use.
Seizures, liver injury and severe poisonings have been reported; causation varies by case.
For scientific and public-health context, consult these primary agency resources. Case reports and surveillance data do not always establish causation.